The analysis of newly diagnosed imatinib-treated CML patients revealed suboptimal OS associated with sustained BCR–ABL transcript levels >10% at three months, >1% at six months, and >35% Philadelphia chromosome-positive metaphases at baseline [32]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.